|
ZFP161 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.22000196004046E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.56800136710922E-11 |
| Normal-vs-Stage2 |
1.006260E-04 |
| Normal-vs-Stage3 |
6.88210044508253E-10 |
| Normal-vs-Stage4 |
4.47790005075888E-09 |
| Stage1-vs-Stage2 |
5.016200E-01 |
| Stage1-vs-Stage3 |
2.690800E-01 |
| Stage1-vs-Stage4 |
1.304760E-01 |
| Stage2-vs-Stage3 |
2.062600E-01 |
| Stage2-vs-Stage4 |
1.060770E-01 |
| Stage3-vs-Stage4 |
5.626800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.43379996553739E-09 |
| Normal-vs-AfricanAmerican |
5.166600E-04 |
| Normal-vs-Asian |
1.405250E-04 |
| Caucasian-vs-AfricanAmerican |
5.790800E-01 |
| Caucasian-vs-Asian |
4.073700E-02 |
| AfricanAmerican-vs-Asian |
3.911800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.57119994792509E-09 |
| Normal-vs-Female |
4.56235049739462E-12 |
| Male-vs-Female |
9.166000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.63690000127326E-09 |
| Normal-vs-Age(41-60Yrs) |
2.33510000224868E-08 |
| Normal-vs-Age(61-80Yrs) |
8.99410002030976E-09 |
| Normal-vs-Age(81-100Yrs) |
1.635050E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.052800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.791000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.011200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.652010E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.378000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.689000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.587900E-02 |
| Classical-VS-Follicular |
2.779500E-02 |
| Classical-VS-Other |
3.345800E-01 |
| Classical-VS-Normal |
6.99090000000346E-07 |
| Tall-VS-Follicular |
8.361800E-01 |
| Tall-VS-Other |
9.006000E-01 |
| Tall-VS-Normal |
7.26900000191932E-08 |
| Follicular-VS-Other |
8.412800E-01 |
| Follicular-VS-Normal |
2.38989994461036E-09 |
| Other-VS-Normal |
7.043400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.70610003691741E-10 |
| Normal-vs-N1 |
1.7075999503291E-09 |
| N0-vs-N1 |
1.488350E-01 |
|
|
